PSU Profiles
Keywords
Last Name
Institution

Diane Thiboutot

TitleProfessor
InstitutionCollege of Medicine
DepartmentDermatology
Address500 University Drive Hershey PA 17033
Phone7175317437

 Overview 
 overview
PREFERRED TITLE/ROLE:

Physician, Professor of Dermatology

GRADUATE PROGRAM AFFILIATIONS:

Molecular Medicine, Biomedical Sciences

EDUCATION:

M.D., Penn State Hershey College of Medicine (1988)
Internship, Penn State Milton S. Hershey Medical Center
Residency, Dermatology, Penn State Milton S. Hershey Medical Center (1992)

NARRATIVE:

Retinoids in cellular apoptosis

The goal of our research (Diane Thiboutot/Amanda Nelson) is to determine the mechanisms by which retinoids induce apoptosis in cancer cells and human sebaceous glands. We have identified a protein mediator of the apoptotic cascade and are examining alternative ways to induce this protein without the use of retinoids. We are also interested in mechanisms of skin cancer migration through tissue particularly with regard to the role of innate immune signaling. Our translational studies use both cell culture and samples from patients and utilize the expertise of the group in gene array expression analysis, microscopy, protein and RNA expression, innate immune signaling in skin cells as well as various aspects of human subjects research.


 Bibliographic 
 selected publications
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
List All   |   Timeline
  1. Clawson GA, Matters GL, Xin P, Imamura-Kawasawa Y, Du Z, Thiboutot DM, Helm KF, Neves RI, Abraham T. Macrophage-Tumor Cell Fusions from Peripheral Blood of Melanoma Patients. PLoS One. 2015; 10(8):e0134320.
    View in: PubMed
  2. Dreno B, Gollnick HP, Kang S, Thiboutot D, Bettoli V, Torres V, Leyden J. Understanding innate immunity and inflammation in acne: implications for management. J Eur Acad Dermatol Venereol. 2015 Jun; 29 Suppl 4:3-11.
    View in: PubMed
  3. Kwon HH, Yoon JY, Park SY, Min S, Kim YI, Park JY, Lee YS, Thiboutot DM, Suh DH. Activity-guided purification identifies lupeol, a pentacyclic triterpene, as a therapeutic agent multiple pathogenic factors of acne. J Invest Dermatol. 2015 Jun; 135(6):1491-500.
    View in: PubMed
  4. Dréno B, Thiboutot D, Layton AM, Berson D, Perez M, Kang S. Large-scale international study enhances understanding of an emerging acne population: adult females. J Eur Acad Dermatol Venereol. 2015 Jun; 29(6):1096-106.
    View in: PubMed
  5. Dreno B, Thiboutot D, Gollnick H, Bettoli V, Kang S, Leyden JJ, Shalita A, Torres V. Antibiotic stewardship in dermatology: limiting antibiotic use in acne. Eur J Dermatol. 2014 May-Jun; 24(3):330-4.
    View in: PubMed
  6. Lee YH, Liu G, Thiboutot DM, Leslie DL, Kirby JS. A retrospective analysis of the duration of oral antibiotic therapy for the treatment of acne among adolescents: investigating practice gaps and potential cost-savings. J Am Acad Dermatol. 2014 Jul; 71(1):70-6.
    View in: PubMed
  7. Del Rosso JQ, Thiboutot D, Gallo R, Webster G, Tanghetti E, Eichenfield LF, Stein-Gold L, Berson D, Zaenglein A. Consensus recommendations from the American Acne & Rosacea Society on the management of rosacea, part 5: a guide on the management of rosacea. Cutis. 2014 Mar; 93(3):134-8.
    View in: PubMed
  8. Thiboutot DM. Inflammasome activation by Propionibacterium acnes: the story of IL-1 in acne continues to unfold. J Invest Dermatol. 2014 Mar; 134(3):595-7.
    View in: PubMed
  9. Tanghetti E, Del Rosso JQ, Thiboutot D, Gallo R, Webster G, Eichenfield LF, Stein-Gold L, Berson D, Zaenglein A. Consensus recommendations from the American acne & rosacea society on the management of rosacea, part 4: a status report on physical modalities and devices. Cutis. 2014 Feb; 93(2):71-6.
    View in: PubMed
  10. Thiboutot DM, Layton AM, Eady EA. IL-17: a key player in the P. acnes inflammatory cascade? J Invest Dermatol. 2014 Feb; 134(2):307-10.
    View in: PubMed
  11. Del Rosso JQ, Thiboutot D, Gallo R, Webster G, Tanghetti E, Eichenfield LF, Stein-Gold L, Berson D, Zaenglein A. Consensus recommendations from the American Acne & Rosacea Society on the management of rosacea, part 3: a status report on systemic therapies. Cutis. 2014 Jan; 93(1):18-28.
    View in: PubMed
  12. Thiboutot D, Dreno B, Gollnick H, Bettoli V, Kang S, Leyden JJ, Shalita A, Torres V. A call to limit antibiotic use in acne. J Drugs Dermatol. 2013 Dec; 12(12):1331-2.
    View in: PubMed
  13. Del Rosso JQ, Thiboutot D, Gallo R, Webster G, Tanghetti E, Eichenfield L, Stein-Gold L, Berson D, Zaenglein A. Consensus recommendations from the American Acne & Rosacea Society on the management of rosacea, part 2: a status report on topical agents. Cutis. 2013 Dec; 92(6):277-84.
    View in: PubMed
  14. Layton A, Thiboutot D. Emerging therapies in rosacea. J Am Acad Dermatol. 2013 Dec; 69(6 Suppl 1):S57-65.
    View in: PubMed
  15. Del Rosso JQ, Thiboutot D, Gallo R, Webster G, Tanghetti E, Eichenfield L, Stein-Gold L, Berson D, Zaenglein A. Consensus recommendations from the American Acne & Rosacea Society on the management of rosacea, part 1: a status report on the disease state, general measures, and adjunctive skin care. Cutis. 2013 Nov; 92(5):234-40.
    View in: PubMed
  16. Zaenglein AL, Shamban A, Webster G, Del Rosso J, Dover JS, Swinyer L, Stein L, Lin X, Draelos Z, Gold M, Thiboutot D. A phase IV, open-label study evaluating the use of triple-combination therapy with minocycline HCl extended-release tablets, a topical antibiotic/retinoid preparation and benzoyl peroxide in patients with moderate to severe acne vulgaris. J Drugs Dermatol. 2013 Jun 1; 12(6):619-25.
    View in: PubMed
  17. Eichenfield LF, Krakowski AC, Piggott C, Del Rosso J, Baldwin H, Friedlander SF, Levy M, Lucky A, Mancini AJ, Orlow SJ, Yan AC, Vaux KK, Webster G, Zaenglein AL, Thiboutot DM. Evidence-based recommendations for the diagnosis and treatment of pediatric acne. Pediatrics. 2013 May; 131 Suppl 3:S163-86.
    View in: PubMed
  18. Thiboutot D, Zaenglein A. Isotretinoin and affective disorders: thirty years later. J Am Acad Dermatol. 2013 Apr; 68(4):675-6.
    View in: PubMed
  19. Del Rosso JQ, Gallo RL, Tanghetti E, Webster G, Thiboutot D. An evaluation of potential correlations between pathophysiologic mechanisms, clinical manifestations, and management of rosacea. Cutis. 2013 Mar; 91(3 Suppl):1-8.
    View in: PubMed
  20. Thiboutot D, Del Rosso JQ. Acne Vulgaris and the Epidermal Barrier: Is Acne Vulgaris Associated with Inherent Epidermal Abnormalities that Cause Impairment of Barrier Functions? Do Any Topical Acne Therapies Alter the Structural and/or Functional Integrity of the Epidermal Barrier? J Clin Aesthet Dermatol. 2013 Feb; 6(2):18-24.
    View in: PubMed
  21. Yoon JY, Kwon HH, Min SU, Thiboutot DM, Suh DH. Epigallocatechin-3-gallate improves acne in humans by modulating intracellular molecular targets and inhibiting P. acnes. J Invest Dermatol. 2013 Feb; 133(2):429-40.
    View in: PubMed
  22. Sharma J, Thiboutot DM, Zaenglein AL. The effects of isotretinoin on wisdom tooth extraction. J Am Acad Dermatol. 2012 Oct; 67(4):794-5.
    View in: PubMed
  23. Clawson GA, Kimchi E, Patrick SD, Xin P, Harouaka R, Zheng S, Berg A, Schell T, Staveley-O'Carroll KF, Neves RI, Mosca PJ, Thiboutot D. Circulating tumor cells in melanoma patients. PLoS One. 2012; 7(7):e41052.
    View in: PubMed
  24. Del Rosso JQ, Gallo RL, Kircik L, Thiboutot D, Baldwin HE, Cohen D. Why is rosacea considered to be an inflammatory disorder? The primary role, clinical relevance, and therapeutic correlations of abnormal innate immune response in rosacea-prone skin. J Drugs Dermatol. 2012 Jun; 11(6):694-700.
    View in: PubMed
  25. Draelos ZD, Shalita AR, Thiboutot D, Oresajo C, Yatskayer M, Raab S. A multicenter, double-blind study to evaluate the efficacy and safety of 2 treatments in participants with mild to moderate acne vulgaris. Cutis. 2012 Jun; 89(6):287-93.
    View in: PubMed
  26. Dispenza MC, Wolpert EB, Gilliland KL, Dai JP, Cong Z, Nelson AM, Thiboutot DM. Systemic isotretinoin therapy normalizes exaggerated TLR-2-mediated innate immune responses in acne patients. J Invest Dermatol. 2012 Sep; 132(9):2198-205.
    View in: PubMed
  27. Dispenza MC, Wolpert EB, Gilliland KL, Dai JP, Cong Z, Nelson AM, Thiboutot DM. J Invest Dermatol. Systemic Isotretinoin Therapy Normalizes Exaggerated TLR-2-Mediated Innate Immune Responses in Acne Patients. 2012.
  28. Thiboutot D, Gollnick H, Bettoli V, Dréno B, Kang S, Leyden JJ, Shalita A, Torres V. Oral isotretinoin and pregnancy prevention programmes. Br J Dermatol. 2012 Feb; 166(2):466-7; author reply 467-8.
    View in: PubMed
  29. Tan J, Wolfe B, Weiss J, Stein-Gold L, Bikowski J, Del Rosso J, Webster GF, Lucky A, Thiboutot D, Wilkin J, Leyden J, Chren MM. Acne severity grading: determining essential clinical components and features using a Delphi consensus. J Am Acad Dermatol. 2012 Aug; 67(2):187-93.
    View in: PubMed
  30. Nelson AM, Cong Z, Gilliland KL, Thiboutot DM. TRAIL contributes to the apoptotic effect of 13-cis retinoic acid in human sebaceous gland cells. Br J Dermatol. 2011 Sep; 165(3):526-33.
    View in: PubMed
  31. Thiboutot D. Dermatologists do not yet fully understand the clinical significance of antibiotic use and bacterial resistance in patients with acne: comment on "Antibiotics, acne, and Staphylococcus aureus colonization. Arch Dermatol. 2011 Aug; 147(8):921-2.
    View in: PubMed
  32. Lumsden KR, Nelson AM, Dispenza MC, Gilliland KL, Cong Z, Zaenglein AL, Thiboutot DM. Isotretinoin increases skin-surface levels of neutrophil gelatinase-associated lipocalin in patients treated for severe acne. Br J Dermatol. 2011 Aug; 165(2):302-10.
    View in: PubMed
  33. Thiboutot D. Rethinking treatment of acne in the severe patient. J Drugs Dermatol. 2011 Jun; 10(6):s8-12.
    View in: PubMed
  34. Bellew S, Thiboutot D, Del Rosso JQ. Pathogenesis of acne vulgaris: what's new, what's interesting and what may be clinically relevant. J Drugs Dermatol. 2011 Jun; 10(6):582-5.
    View in: PubMed
  35. Thiboutot D. Introduction. Challenges in managing acne patients. J Drugs Dermatol. 2011 Jun; 10(6):s7.
    View in: PubMed
  36. Leyden JJ, Gollnick H, Thiboutot D, Dreno B, Bettoli V, Kang S, Shalita A, Torres V. The hypothetical role of FoxO1 in acne is interesting, but more study is needed before any conclusions can be drawn. Br J Dermatol. 2010 Dec; 163(6):1365-6; author reply 1366-7.
    View in: PubMed
  37. Webster G, Thiboutot DM, Chen DM, Merikle E. Impact of a fixed combination of clindamycin phosphate 1.2%-benzoyl peroxide 2.5% aqueous gel on health-related quality of life in moderate to severe acne vulgaris. Cutis. 2010 Nov; 86(5):263-7.
    View in: PubMed
  38. Janiczek-Dolphin N, Cook J, Thiboutot D, Harness J, Clucas A. Can sebum reduction predict acne outcome? Br J Dermatol. 2010 Oct; 163(4):683-8.
    View in: PubMed
  39. Santen RJ, Allred DC, Ardoin SP, Archer DF, Boyd N, Braunstein GD, Burger HG, Colditz GA, Davis SR, Gambacciani M, Gower BA, Henderson VW, Jarjour WN, Karas RH, Kleerekoper M, Lobo RA, Manson JE, Marsden J, Martin KA, Martin L, Pinkerton JV, Rubinow DR, Teede H, Thiboutot DM, Utian WH. Postmenopausal hormone therapy: an Endocrine Society scientific statement. J Clin Endocrinol Metab. 2010 Jul; 95(7 Suppl 1):s1-s66.
    View in: PubMed
  40. Dréno B, Thiboutot D, Gollnick H, Finlay AY, Layton A, Leyden JJ, Leutenegger E, Perez M. Large-scale worldwide observational study of adherence with acne therapy. Int J Dermatol. 2010 Apr; 49(4):448-56.
    View in: PubMed
  41. Eichenfield LF, Thiboutot D, Shalita A, Swinyer L, Tanghetti E, Tschen E, Parr L. A Three-Step Acne System Containing Solubilized Benzoyl Peroxide versus Benzoyl Peroxide/Clindamycin in Pediatric Patients with Acne. J Clin Aesthet Dermatol. 2009 Nov; 2(11):21-6.
    View in: PubMed
  42. Kircik L, Green L, Thiboutot D, Tanghetti E, Wilson D, Dhawan S, Parr L. Comparing a novel solubilized benzoyl peroxide gel with benzoyl peroxide/clindamycin: final data from a multicenter, investigator-blind, randomized study. J Drugs Dermatol. 2009 Sep; 8(9):812-8.
    View in: PubMed
  43. Odom R, Dahl M, Dover J, Draelos Z, Drake L, Macsai M, Powell F, Thiboutot D, Webster GF, Wilkin J. Standard management options for rosacea, part 2: options according to subtype. Cutis. 2009 Aug; 84(2):97-104.
    View in: PubMed
  44. Odom R, Dahl M, Dover J, Draelos Z, Drake L, Macsai M, Powell F, Thiboutot D, Webster GF, Wilkin J. Standard management options for rosacea, part 1: overview and broad spectrum of care. Cutis. 2009 Jul; 84(1):43-7.
    View in: PubMed
  45. Thiboutot D, Eichenfield L, Shalita A, Del Rosso JQ, Swinyer L, Tanghetti E, Tschen E, Parr L. A 3-step acne system containing solubilized benzoyl peroxide versus clindamycin-benzoyl peroxide. Cutis. 2009 Jul; 84(1):48-55.
    View in: PubMed
  46. Thiboutot DM, Fleischer AB, Del Rosso JQ, Rich P. A multicenter study of topical azelaic acid 15% gel in combination with oral doxycycline as initial therapy and azelaic acid 15% gel as maintenance monotherapy. J Drugs Dermatol. 2009 Jul; 8(7):639-48.
    View in: PubMed
  47. Lee DY, Huang CM, Nakatsuji T, Thiboutot D, Kang SA, Monestier M, Gallo RL. Histone H4 is a major component of the antimicrobial action of human sebocytes. J Invest Dermatol. 2009 Oct; 129(10):2489-96.
    View in: PubMed
  48. Nelson AM, Zhao W, Gilliland KL, Zaenglein AL, Liu W, Thiboutot DM. Temporal changes in gene expression in the skin of patients treated with isotretinoin provide insight into its mechanism of action. Dermatoendocrinol. 2009 May; 1(3):177-87.
    View in: PubMed
  49. Thiboutot D, Gollnick H, Bettoli V, Dréno B, Kang S, Leyden JJ, Shalita AR, Lozada VT, Berson D, Finlay A, Goh CL, Herane MI, Kaminsky A, Kubba R, Layton A, Miyachi Y, Perez M, Martin JP, Ramos-E-Silva M, See JA, Shear N, Wolf J. New insights into the management of acne: an update from the Global Alliance to Improve Outcomes in Acne group. J Am Acad Dermatol. 2009 May; 60(5 Suppl):S1-50.
    View in: PubMed
  50. Nelson AM, Zhao W, Gilliland KL, Zaenglein AL, Liu W, Thiboutot DM. Early gene changes induced by isotretinoin in the skin provide clues to its mechanism of action. Dermatoendocrinol. 2009 Mar; 1(2):100-1.
    View in: PubMed
  51. Ghali F, Kang S, Leyden J, Shalita AR, Thiboutot DM. Changing the face of acne therapy. Cutis. 2009 Feb; 83(2 Suppl):4-15.
    View in: PubMed
  52. Nelson AM, Zhao W, Gilliland KL, Zaenglein AL, Liu W, Thiboutot DM. Isotretinoin temporally regulates distinct sets of genes in patient skin. J Invest Dermatol. 2009 Apr; 129(4):1038-42.
    View in: PubMed
  53. Arbuckle R, Atkinson MJ, Clark M, Abetz L, Lohs J, Kuhagen I, Harness J, Draelos Z, Thiboutot D, Blume-Peytavi U, Copley-Merriman K. Patient experiences with oily skin: the qualitative development of content for two new patient reported outcome questionnaires. Health Qual Life Outcomes. 2008; 6:80.
    View in: PubMed
  54. Thiboutot D, Zaenglein A, Weiss J, Webster G, Calvarese B, Chen D. An aqueous gel fixed combination of clindamycin phosphate 1.2% and benzoyl peroxide 2.5% for the once-daily treatment of moderate to severe acne vulgaris: assessment of efficacy and safety in 2813 patients. J Am Acad Dermatol. 2008 Nov; 59(5):792-800.
    View in: PubMed
  55. George R, Clarke S, Thiboutot D. Hormonal therapy for acne. Semin Cutan Med Surg. 2008 Sep; 27(3):188-96.
    View in: PubMed
  56. Lucky AW, Koltun W, Thiboutot D, Niknian M, Sampson-Landers C, Korner P, Marr J. A combined oral contraceptive containing 3-mg drospirenone/ 20-microg ethinyl estradiol in the treatment of acne vulgaris: a randomized, double-blind, placebo-controlled study evaluating lesion counts and participant self-assessment. Cutis. 2008 Aug; 82(2):143-50.
    View in: PubMed
  57. Del Rosso JQ, Leyden JJ, Thiboutot D, Webster GF. Antibiotic use in acne vulgaris and rosacea: clinical considerations and resistance issues of significance to dermatologists. Cutis. 2008 Aug; 82(2 Suppl 2):5-12.
    View in: PubMed
  58. Weiss JS, Thiboutot DM, Hwa J, Liu Y, Graeber M. Long-term safety and efficacy study of adapalene 0.3% gel. J Drugs Dermatol. 2008 Jun; 7(6 Suppl):s24-8.
    View in: PubMed
  59. Thiboutot D, Arsonnaud S, Soto P. Efficacy and tolerability of adapalene 0.3% gel compared to tazarotene 0.1% gel in the treatment of acne vulgaris. J Drugs Dermatol. 2008 Jun; 7(6 Suppl):s3-10.
    View in: PubMed
  60. Thiboutot DM, Fleischer AB, Del Rosso JQ, Graupe K. Azelaic acid 15% gel once daily versus twice daily in papulopustular rosacea. J Drugs Dermatol. 2008 Jun; 7(6):541-6.
    View in: PubMed
  61. Nelson AM, Zhao W, Gilliland KL, Zaenglein AL, Liu W, Thiboutot DM. Neutrophil gelatinase-associated lipocalin mediates 13-cis retinoic acid-induced apoptosis of human sebaceous gland cells. J Clin Invest. 2008 Apr; 118(4):1468-78.
    View in: PubMed
  62. Koltun W, Lucky AW, Thiboutot D, Niknian M, Sampson-Landers C, Korner P, Marr J. Efficacy and safety of 3 mg drospirenone/20 mcg ethinylestradiol oral contraceptive administered in 24/4 regimen in the treatment of acne vulgaris: a randomized, double-blind, placebo-controlled trial. Contraception. 2008 Apr; 77(4):249-56.
    View in: PubMed
  63. Thiboutot DM. Overview of acne and its treatment. Cutis. 2008 Jan; 81(1 Suppl):3-7.
    View in: PubMed
  64. Thiboutot DM, Harper JC, O'Connell K, Rich P, Sondheimer SJ. Improving outcomes through collaboration. Cutis. 2008 Jan; 81(1 Suppl):26-31.
    View in: PubMed
  65. Thiboutot D, Dréno B, Layton A. Acne counseling to improve adherence. Cutis. 2008 Jan; 81(1):81-6.
    View in: PubMed
  66. Thiboutot D. Versatility of azelaic acid 15% gel in treatment of inflammatory acne vulgaris. J Drugs Dermatol. 2008 Jan; 7(1):13-6.
    View in: PubMed
  67. Smith TM, Gilliland K, Clawson GA, Thiboutot D. IGF-1 induces SREBP-1 expression and lipogenesis in SEB-1 sebocytes via activation of the phosphoinositide 3-kinase/Akt pathway. J Invest Dermatol. 2008 May; 128(5):1286-93.
    View in: PubMed
  68. Smith KR, Thiboutot DM. Thematic review series: skin lipids. Sebaceous gland lipids: friend or foe? J Lipid Res. 2008 Feb; 49(2):271-81.
    View in: PubMed
  69. Berger R, Barba A, Fleischer A, Leyden JJ, Lucky A, Pariser D, Rafal E, Thiboutot D, Wilson D, Grossman R, Nighland M. A double-blinded, randomized, vehicle-controlled, multicenter, parallel-group study to assess the safety and efficacy of tretinoin gel microsphere 0.04% in the treatment of acne vulgaris in adults. Cutis. 2007 Aug; 80(2):152-7.
    View in: PubMed
  70. Thiboutot DM, Weiss J, Bucko A, Eichenfield L, Jones T, Clark S, Liu Y, Graeber M, Kang S. Adapalene-benzoyl peroxide, a fixed-dose combination for the treatment of acne vulgaris: results of a multicenter, randomized double-blind, controlled study. J Am Acad Dermatol. 2007 Nov; 57(5):791-9.
    View in: PubMed
  71. Clarke SB, Nelson AM, George RE, Thiboutot DM. Pharmacologic modulation of sebaceous gland activity: mechanisms and clinical applications. Dermatol Clin. 2007 Apr; 25(2):137-46, v.
    View in: PubMed
  72. Strauss JS, Krowchuk DP, Leyden JJ, Lucky AW, Shalita AR, Siegfried EC, Thiboutot DM, Van Voorhees AS, Beutner KA, Sieck CK, Bhushan R. Guidelines of care for acne vulgaris management. J Am Acad Dermatol. 2007 Apr; 56(4):651-63.
    View in: PubMed
  73. Thiboutot DM, Willmer J, Sharata H, Halder R, Garrett S. Pharmacokinetics of dapsone gel, 5% for the treatment of acne vulgaris. Clin Pharmacokinet. 2007; 46(8):697-712.
    View in: PubMed
  74. Del Rosso JQ, Baum EW, Draelos ZD, Elewski BE, Fleischer AB, Kakita LS, Thiboutot D. Azelaic acid gel 15%: clinical versatility in the treatment of rosacea. Cutis. 2006 Nov; 78(5 Suppl):6-19.
    View in: PubMed
  75. Zaenglein AL, Thiboutot DM. Expert committee recommendations for acne management. Pediatrics. 2006 Sep; 118(3):1188-99.
    View in: PubMed
  76. Thiboutot DM, Gollnick HP. Treatment considerations for inflammatory acne: clinical evidence for adapalene 0.1% in combination therapies. J Drugs Dermatol. 2006 Sep; 5(8):785-94.
    View in: PubMed
  77. Thiboutot DM, Cockerell CJ. iPLEDGE: A Report from the Front Lines of Dermatologic Practice. Virtual Mentor. 2006; 8(8):524-8.
    View in: PubMed
  78. Smith TM, Cong Z, Gilliland KL, Clawson GA, Thiboutot DM. Insulin-like growth factor-1 induces lipid production in human SEB-1 sebocytes via sterol response element-binding protein-1. J Invest Dermatol. 2006 Jun; 126(6):1226-32.
    View in: PubMed
  79. Trivedi NR, Cong Z, Nelson AM, Albert AJ, Rosamilia LL, Sivarajah S, Gilliland KL, Liu W, Mauger DT, Gabbay RA, Thiboutot DM. Peroxisome proliferator-activated receptors increase human sebum production. J Invest Dermatol. 2006 Sep; 126(9):2002-9.
    View in: PubMed
  80. Thiboutot DM, Shalita AR, Yamauchi PS, Dawson C, Kerrouche N, Arsonnaud S, Kang S. Adapalene gel, 0.1%, as maintenance therapy for acne vulgaris: a randomized, controlled, investigator-blind follow-up of a recent combination study. Arch Dermatol. 2006 May; 142(5):597-602.
    View in: PubMed
  81. Leyden J, Thiboutot DM, Shalita AR, Webster G, Washenik K, Strober BE, Shupack J. Comparison of tazarotene and minocycline maintenance therapies in acne vulgaris: a multicenter, double-blind, randomized, parallel-group study. Arch Dermatol. 2006 May; 142(5):605-12.
    View in: PubMed
  82. Trivedi NR, Gilliland KL, Zhao W, Liu W, Thiboutot DM. Gene array expression profiling in acne lesions reveals marked upregulation of genes involved in inflammation and matrix remodeling. J Invest Dermatol. 2006 May; 126(5):1071-9.
    View in: PubMed
  83. Nelson AM, Gilliland KL, Cong Z, Thiboutot DM. 13-cis Retinoic acid induces apoptosis and cell cycle arrest in human SEB-1 sebocytes. J Invest Dermatol. 2006 Oct; 126(10):2178-89.
    View in: PubMed
  84. Thiboutot D, Pariser DM, Egan N, Flores J, Herndon JH, Kanof NB, Kempers SE, Maddin S, Poulin YP, Wilson DC, Hwa J, Liu Y, Graeber M. Adapalene gel 0.3% for the treatment of acne vulgaris: a multicenter, randomized, double-blind, controlled, phase III trial. J Am Acad Dermatol. 2006 Feb; 54(2):242-50.
    View in: PubMed
  85. Elewski B, Thiboutot D. A clinical overview of azelaic acid. Cutis. 2006 Feb; 77(2 Suppl):12-6.
    View in: PubMed
  86. Pariser DM, Thiboutot DM, Clark SD, Jones TM, Liu Y, Graeber M. The efficacy and safety of adapalene gel 0.3% in the treatment of acne vulgaris: A randomized, multicenter, investigator-blinded, controlled comparison study versus adapalene gel 0.1% and vehicle. Cutis. 2005 Aug; 76(2):145-51.
    View in: PubMed
  87. Thiboutot DM, Shalita AR, Yamauchi PS, Dawson C, Arsonnaud S, Kang S. Combination therapy with adapalene gel 0.1% and doxycycline for severe acne vulgaris: a multicenter, investigator-blind, randomized, controlled study. Skinmed. 2005 May-Jun; 4(3):138-46.
    View in: PubMed
  88. Mackley CL, Thiboutot DM. Diagnosing and managing the patient with rosacea. Cutis. 2005 Apr; 75(4 Suppl):25-9.
    View in: PubMed
  89. Cappel M, Mauger D, Thiboutot D. Correlation between serum levels of insulin-like growth factor 1, dehydroepiandrosterone sulfate, and dihydrotestosterone and acne lesion counts in adult women. Arch Dermatol. 2005 Mar; 141(3):333-8.
    View in: PubMed
  90. Leyden JJ, Shalita A, Thiboutot D, Washenik K, Webster G. Topical retinoids in inflammatory acne: a retrospective, investigator-blinded, vehicle-controlled, photographic assessment. Clin Ther. 2005 Feb; 27(2):216-24.
    View in: PubMed
  91. Shalita AR, Berson DS, Thiboutot DM, Leyden JJ, Parizadeh D, Sefton J, Walker PS, Gibson JR. Effects of tazarotene 0.1 % cream in the treatment of facial acne vulgaris: pooled results from two multicenter, double-blind, randomized, vehicle-controlled, parallel-group trials. Clin Ther. 2004 Nov; 26(11):1865-73.
    View in: PubMed
  92. Thiboutot D. Acne: hormonal concepts and therapy. Clin Dermatol. 2004 Sep-Oct; 22(5):419-28.
    View in: PubMed
  93. Clawson GA, Miranda GQ, Sivarajah A, Xin P, Pan W, Thiboutot D, Christensen ND. Inhibition of papilloma progression by antisense oligonucleotides targeted to HPV11 E6/E7 RNA. Gene Ther. 2004 Sep; 11(17):1331-41.
    View in: PubMed
  94. Thiboutot D. Regulation of human sebaceous glands. J Invest Dermatol. 2004 Jul; 123(1):1-12.
    View in: PubMed
  95. Goldsmith LA, Bolognia JL, Callen JP, Chen SC, Feldman SR, Lim HW, Lucky AW, Reed BR, Siegfried EC, Thiboutot DM, Wheeland RG. American Academy of Dermatology Consensus Conference on the safe and optimal use of isotretinoin: summary and recommendations. J Am Acad Dermatol. 2004 Jun; 50(6):900-6.
    View in: PubMed
  96. Leyden JJ, Thiboutot D, Shalita A. Photographic review of results from a clinical study comparing benzoyl peroxide 5%/clindamycin 1% topical gel with vehicle in the treatment of rosacea. Cutis. 2004 Jun; 73(6 Suppl):11-7.
    View in: PubMed
  97. Leyden J, Bergfeld W, Drake L, Dunlap F, Goldman MP, Gottlieb AB, Heffernan MP, Hickman JG, Hordinsky M, Jarrett M, Kang S, Lucky A, Peck G, Phillips T, Rapaport M, Roberts J, Savin R, Sawaya ME, Shalita A, Shavin J, Shaw JC, Stein L, Stewart D, Strauss J, Swinehart J, Swinyer L, Thiboutot D, Washenik K, Weinstein G, Whiting D, Pappas F, Sanchez M, Terranella L, Waldstreicher J. A systemic type I 5 alpha-reductase inhibitor is ineffective in the treatment of acne vulgaris. J Am Acad Dermatol. 2004 Mar; 50(3):443-7.
    View in: PubMed
  98. Gollnick H, Cunliffe W, Berson D, Dreno B, Finlay A, Leyden JJ, Shalita AR, Thiboutot D. Management of acne: a report from a Global Alliance to Improve Outcomes in Acne. J Am Acad Dermatol. 2003 Jul; 49(1 Suppl):S1-37.
    View in: PubMed
  99. Thiboutot D, Thieroff-Ekerdt R, Graupe K. Efficacy and safety of azelaic acid (15%) gel as a new treatment for papulopustular rosacea: results from two vehicle-controlled, randomized phase III studies. J Am Acad Dermatol. 2003 Jun; 48(6):836-45.
    View in: PubMed
  100. Thiboutot D, Jabara S, McAllister JM, Sivarajah A, Gilliland K, Cong Z, Clawson G. Human skin is a steroidogenic tissue: steroidogenic enzymes and cofactors are expressed in epidermis, normal sebocytes, and an immortalized sebocyte cell line (SEB-1). J Invest Dermatol. 2003 Jun; 120(6):905-14.
    View in: PubMed
  101. McGarrity TJ, Wagner Baker MJ, Ruggiero FM, Thiboutot DM, Hampel H, Zhou XP, Eng C. GI polyposis and glycogenic acanthosis of the esophagus associated with PTEN mutation positive Cowden syndrome in the absence of cutaneous manifestations. Am J Gastroenterol. 2003 Jun; 98(6):1429-34.
    View in: PubMed
  102. Thiboutot D, Chen W. Update and future of hormonal therapy in acne. Dermatology. 2003; 206(1):57-67.
    View in: PubMed
  103. Harper JC, Thiboutot DM. Pathogenesis of acne: recent research advances. Adv Dermatol. 2003; 19:1-10.
    View in: PubMed
  104. Thiboutot DM, Strauss JS. Diet and acne revisited. Arch Dermatol. 2002 Dec; 138(12):1591-2.
    View in: PubMed
  105. Chen W, Thiboutot D, Zouboulis CC. Cutaneous androgen metabolism: basic research and clinical perspectives. J Invest Dermatol. 2002 Nov; 119(5):992-1007.
    View in: PubMed
  106. Thiboutot D. Acne: 1991-2001. J Am Acad Dermatol. 2002 Jul; 47(1):109-17.
    View in: PubMed
  107. Thiboutot D, Jarratt M, Rich P, Rist T, Rodriguez D, Levy S. A randomized, parallel, vehicle-controlled comparison of two erythromycin/benzoyl peroxide preparations for acne vulgaris. Clin Ther. 2002 May; 24(5):773-85.
    View in: PubMed
  108. Thiboutot D, Gold MH, Jarratt MT, Kang S, Kaplan DL, Millikan L, Wolfe J, Loesche C, Baker M. Randomized controlled trial of the tolerability, safety, and efficacy of adapalene gel 0.1% and tretinoin microsphere gel 0.1% for the treatment of acne vulgaris. Cutis. 2001 Oct; 68(4 Suppl):10-9.
    View in: PubMed
  109. Thiboutot D. Hormones and acne: pathophysiology, clinical evaluation, and therapies. Semin Cutan Med Surg. 2001 Sep; 20(3):144-53.
    View in: PubMed
  110. Thiboutot D. Acne. Introduction. Semin Cutan Med Surg. 2001 Sep; 20(3):137-8.
    View in: PubMed
  111. Thiboutot D, Archer DF, Lemay A, Washenik K, Roberts J, Harrison DD. A randomized, controlled trial of a low-dose contraceptive containing 20 microg of ethinyl estradiol and 100 microg of levonorgestrel for acne treatment. Fertil Steril. 2001 Sep; 76(3):461-8.
    View in: PubMed
  112. Martin AR, Lookingbill DP, Botek A, Light J, Thiboutot D, Girman CJ. Health-related quality of life among patients with facial acne -- assessment of a new acne-specific questionnaire. Clin Exp Dermatol. 2001 Jul; 26(5):380-5.
    View in: PubMed
  113. Thiboutot DM. Endocrinological evaluation and hormonal therapy for women with difficult acne. J Eur Acad Dermatol Venereol. 2001; 15 Suppl 3:57-61.
    View in: PubMed
  114. Thiboutot D, Sivarajah A, Gilliland K, Cong Z, Clawson G. The melanocortin 5 receptor is expressed in human sebaceous glands and rat preputial cells. J Invest Dermatol. 2000 Oct; 115(4):614-9.
    View in: PubMed
  115. Thiboutot D, Bayne E, Thorne J, Gilliland K, Flanagan J, Shao Q, Light J, Helm K. Immunolocalization of 5alpha-reductase isozymes in acne lesions and normal skin. Arch Dermatol. 2000 Sep; 136(9):1125-9.
    View in: PubMed
  116. Thiboutot D. New treatments and therapeutic strategies for acne. Arch Fam Med. 2000 Feb; 9(2):179-87.
    View in: PubMed
  117. Thiboutot DM. Acne and rosacea. New and emerging therapies. Dermatol Clin. 2000 Jan; 18(1):63-71, viii.
    View in: PubMed
  118. Thiboutot D. Propecia dosages. Arch Dermatol. 1999 Nov; 135(11):1417.
    View in: PubMed
  119. Drake L, Hordinsky M, Fiedler V, Swinehart J, Unger WP, Cotterill PC, Thiboutot DM, Lowe N, Jacobson C, Whiting D, Stieglitz S, Kraus SJ, Griffin EI, Weiss D, Carrington P, Gencheff C, Cole GW, Pariser DM, Epstein ES, Tanaka W, Dallob A, Vandormael K, Geissler L, Waldstreicher J. The effects of finasteride on scalp skin and serum androgen levels in men with androgenetic alopecia. J Am Acad Dermatol. 1999 Oct; 41(4):550-4.
    View in: PubMed
  120. Thiboutot D, Gilliland K, Light J, Lookingbill D. Androgen metabolism in sebaceous glands from subjects with and without acne. Arch Dermatol. 1999 Sep; 135(9):1041-5.
    View in: PubMed
  121. Bayne EK, Flanagan J, Einstein M, Ayala J, Chang B, Azzolina B, Whiting DA, Mumford RA, Thiboutot D, Singer II, Harris G. Immunohistochemical localization of types 1 and 2 5alpha-reductase in human scalp. Br J Dermatol. 1999 Sep; 141(3):481-91.
    View in: PubMed
  122. Leyden J, Dunlap F, Miller B, Winters P, Lebwohl M, Hecker D, Kraus S, Baldwin H, Shalita A, Draelos Z, Markou M, Thiboutot D, Rapaport M, Kang S, Kelly T, Pariser D, Webster G, Hordinsky M, Rietschel R, Katz HI, Terranella L, Best S, Round E, Waldstreicher J. Finasteride in the treatment of men with frontal male pattern hair loss. J Am Acad Dermatol. 1999 Jun; 40(6 Pt 1):930-7.
    View in: PubMed
  123. Thiboutot D, Martin P, Volikos L, Gilliland K. Oxidative activity of the type 2 isozyme of 17beta-hydroxysteroid dehydrogenase (17beta-HSD) predominates in human sebaceous glands. J Invest Dermatol. 1998 Sep; 111(3):390-5.
    View in: PubMed
  124. Thiboutot D, Knaggs H, Gilliland K, Lin G. Activity of 5-alpha-reductase and 17-beta-hydroxysteroid dehydrogenase in the infrainfundibulum of subjects with and without acne vulgaris. Dermatology. 1998; 196(1):38-42.
    View in: PubMed
  125. Thiboutot DM, Knaggs H, Gilliland K, Hagari S. Activity of type 1 5 alpha-reductase is greater in the follicular infrainfundibulum compared with the epidermis. Br J Dermatol. 1997 Feb; 136(2):166-71.
    View in: PubMed
  126. Thiboutot DM. Acne. An overview of clinical research findings. Dermatol Clin. 1997 Jan; 15(1):97-109.
    View in: PubMed
  127. Girman CJ, Hartmaier S, Thiboutot D, Johnson J, Barber B, DeMuro-Mercon C, Waldstreicher J. Evaluating health-related quality of life in patients with facial acne: development of a self-administered questionnaire for clinical trials. Qual Life Res. 1996 Oct; 5(5):481-90.
    View in: PubMed
  128. Long D, Thiboutot DM, Majeski JT, Vasily DB, Helm KF. Interstitial granulomatous dermatitis with arthritis. J Am Acad Dermatol. 1996 Jun; 34(6):957-61.
    View in: PubMed
  129. Thiboutot DM. An overview of acne and its treatment. Cutis. 1996 Jan; 57(1 Suppl):8-12.
    View in: PubMed
  130. Thiboutot DM. Clinical review 74: Dermatological manifestations of endocrine disorders. J Clin Endocrinol Metab. 1995 Oct; 80(10):3082-7.
    View in: PubMed
  131. Thiboutot D, Harris G, Iles V, Cimis G, Gilliland K, Hagari S. Activity of the type 1 5 alpha-reductase exhibits regional differences in isolated sebaceous glands and whole skin. J Invest Dermatol. 1995 Aug; 105(2):209-14.
    View in: PubMed
  132. Thiboutot DM, Lookingbill DP. Acne: acute or chronic disease? J Am Acad Dermatol. 1995 May; 32(5 Pt 3):S2-5.
    View in: PubMed
  133. Thiboutot DM. Acne rosacea. Am Fam Physician. 1994 Dec; 50(8):1691-7, 1701-2.
    View in: PubMed
  134. Madden SD, Thiboutot DM, Marks JG. Occupationally induced allergic contact dermatitis to methylchloroisothiazolinone/methylisothiazolinone among machinists. J Am Acad Dermatol. 1994 Feb; 30(2 Pt 1):272-4.
    View in: PubMed
  135. Thiboutot DM, Beckford A, Mart CR, Sexton M, Maloney ME. Cytomegalovirus diaper dermatitis. Arch Dermatol. 1991 Mar; 127(3):396-8.
    View in: PubMed
  136. Thiboutot DM, Hamory BH, Marks JG. Dermatoses among floral shop workers. J Am Acad Dermatol. 1990 Jan; 22(1):54-8.
    View in: PubMed
Thiboutot's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts
_
Co-Authors
_
Similar People
_
Same Department
Physical Neighbors
_